Polymorphisms of estrogen receptor alpha in prostate cancer

Estrogen receptor (ER) α polymorphisms have been shown to be involved in the oncogenesis of several organs. We hypothesize that polymorphisms of the ERα gene are risk factors for prostate cancer. The genotypic distributions of six different loci (codons: 10 T → C, 87 G → C, 243 C → T, 325 C → G, 594 G → A, and intron 1 C → T) of the ERα gene were analyzed in prostate cancer tissues. The DNA from 115 cases of prostate cancer (Japanese population) was analyzed by sequence‐specific polymerase chain reaction (PCR) and direct sequencing to determine the genotypic and allelic frequencies of the six different polymorphic loci of ERα. The relative risk of variant genotype was calculated by comparison with 200 healthy controls. Results of this study showed that the frequency of the variant genotype (C/C) on codon 10 was significantly higher in prostate cancer patients. The odds ratio (OR) was calculated as 3.26 compared to wild‐type (T/T) with a 95% confidence interval (CI) of 1.58–6.73. Allele frequency at codon 10 also differed between groups. No association was found between codon 10 polymorphism and the stage of cancer. Polymorphism was not observed in codon 87, and frequencies of genotypes and alleles at other loci (intron 1, codons 243, 325, and 594) were not statistically different between cancer and controls. The present study suggests that polymorphism in codon 10 of ERα may be a risk factor for prostate cancer. These results are important in understanding the role of ERα polymorphism in the pathogenesis of prostate cancer. © 2003 Wiley‐Liss, Inc.

[1]  R. Dahiya,et al.  Single nucleotide polymorphisms of estrogen receptor alpha in human renal cell carcinoma. , 2002, Biochemical and biophysical research communications.

[2]  J. Reichardt,et al.  Hormones and prostate cancer: Current perspectives and future directions , 2002, The Prostate.

[3]  S. Coughlin,et al.  A review of genetic polymorphisms and prostate cancer risk. , 2002, Annals of epidemiology.

[4]  C. Sites,et al.  Selective modulation of sex steroids , 2002, Ageing Research Reviews.

[5]  E. Cavalieri,et al.  Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. , 2002, Carcinogenesis.

[6]  R. Dahiya,et al.  Single nucleotide polymorphisms of estrogen receptor alpha in human renal cell carcinoma. , 2002, Biochemical and biophysical research communications.

[7]  Y. Ouchi,et al.  Differential Expression of Estrogen Receptor β (ERβ) and Its C-Terminal Truncated Splice Variant ERβcx as Prognostic Predictors in Human Prostatic Cancer , 2001 .

[8]  M. Murai,et al.  Expression of Estrogen Receptor (ER–α and ER–β) mRNA in Human Prostate Cancer , 2001, European Urology.

[9]  J. Cauley,et al.  Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Frydenberg,et al.  A case–control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects , 2001, Cancer.

[11]  P. Lakatos,et al.  Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. , 2001, European journal of cancer.

[12]  R. Lea,et al.  Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer , 2001, International journal of cancer.

[13]  I. Leav,et al.  Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .

[14]  M. Kitagawa,et al.  CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic Activity* , 2001, The Journal of Biological Chemistry.

[15]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[16]  F. Bethencourt,et al.  Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. , 2001, The Journal of endocrinology.

[17]  Y. Ouchi,et al.  Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. , 2001, Biochemical and biophysical research communications.

[18]  I. Leav,et al.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. , 2001, The American journal of pathology.

[19]  M. Murai,et al.  Expression of estrogen receptor (ER-alpha and ER-beta) mRNA in human prostate cancer. , 2001, European urology.

[20]  M. Urbančíková,et al.  Intracellular estrogen receptors, their characterization and function (Review). , 2000, Endocrine regulations.

[21]  T. Habuchi,et al.  Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. , 2000, Cancer research.

[22]  N. Roodi,et al.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. , 2000, Cancer research.

[23]  C. Ambrosone,et al.  Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. , 2000, Journal of the National Cancer Institute. Monographs.

[24]  B. Pikounis,et al.  Estradiol causes a dose‐dependent stimulation of prostate growth in castrated beagle dogs , 2000, The Prostate.

[25]  H. Melhus,et al.  Estrogen receptor α gene polymorphisms and endometrial cancer risk , 2000 .

[26]  H. Melhus,et al.  Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. , 2000, Carcinogenesis.

[27]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[28]  T. Shimada,et al.  Catalytic properties of polymorphic human cytochrome P450 1B1 variants. , 1999, Carcinogenesis.

[29]  H. Bonkhoff,et al.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. , 1999, The American journal of pathology.

[30]  M. Parker,et al.  Molecular mechanisms of steroid hormone action , 1998 .

[31]  F. Oesch,et al.  Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[32]  M Ingelman-Sundberg,et al.  A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. , 1997, Molecular pharmacology.

[33]  T. Therneau,et al.  Relationship between DNA ploidy and functional estrogen receptors in operable prostate cancer. , 1997, European urology.

[34]  C. Mathew,et al.  Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. , 1996, Cancer letters.

[35]  J. Lo-Guidice,et al.  Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility. , 1996, Carcinogenesis.

[36]  F. Guengerich,et al.  Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. , 1996, Cancer research.

[37]  O. Yoshida,et al.  Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers , 1995, Japanese journal of cancer research : Gann.

[38]  M. Bosland,et al.  Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. , 1995, Carcinogenesis.

[39]  G. Carruba,et al.  Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. , 1995, Endocrinology.

[40]  J. Liehr,et al.  Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone. , 1995, Carcinogenesis.

[41]  N. Roodi,et al.  Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. , 1995, Journal of the National Cancer Institute.

[42]  Kazuto Ito,et al.  Synergistic effects of estrogen and androgen on the prostate: Effects of estrogen on androgen‐and estrogen‐receptors, BrdU uptake, immunohistochemical study of AR, and responses to antiandrogens , 1995, The Prostate.

[43]  S. Lehrer,et al.  Estrogen receptor variant and hypertension in women. , 1993, Hypertension.

[44]  B. E. Walker,et al.  Pituitary tumors in mice exposed prenatally to diethylstilbestrol. , 1993, Cancer research.

[45]  N. Golden,et al.  in Women with , 1992 .

[46]  M. Soloway,et al.  Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues , 1992, The Prostate.

[47]  W D Dupont,et al.  Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. , 1992, Cancer research.

[48]  A. Levine,et al.  Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy. , 1991, The Journal of urology.

[49]  J. McLachlan,et al.  Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. , 1990, Cancer research.

[50]  S. Thung,et al.  Oestrogen receptor B-region polymorphism and spontaneous abortion in women with breast cancer , 1990, The Lancet.

[51]  N. Olea,et al.  Negative controls of cell proliferation: human prostate cancer cells and androgens. , 1989, Cancer research.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  I. Leav,et al.  Androgen‐supported estrogen‐enhanced epithelial proliferation in the prostates of intact noble rats , 1989, The Prostate.

[54]  A. Schuurmans,et al.  Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids , 1988, International journal of cancer.

[55]  P. Chambon,et al.  Genomic organization of the human oestrogen receptor gene. , 1988, The EMBO journal.

[56]  M. Rio,et al.  Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. , 1988, Cancer treatment and research.

[57]  I. Leav,et al.  Ultrastructural and biochemical expressions of divergent differentiation in prostates of castrated dogs treated with estrogen and androgen. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[58]  R. A. Huseby.  Demonstration of a direct carcinogenic effect of estradiol on Leydig cells of the mouse. , 1980, Cancer research.

[59]  L. Jones,et al.  Transplantability and sex steroid hormone responsiveness of cervicovaginal tumors derived from female BALB/cCrgl mice neonatally treated with ovarian steroids. , 1979, Cancer research.

[60]  I. Leav,et al.  Bipotentiality of response to sex hormones by the prostate of castrated or hypophysectomized dogs. Direct effects of estrogen. , 1978, The American journal of pathology.